Blog
RSS FeedPosted by Michael Wonder on 21 Feb 2025
Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology
19 February 2025 - Surrogate endpoints, used to substitute for and predict final clinical outcomes, are increasingly being used to support ...
Posted by Michael Wonder on 19 Feb 2025
Selpercatinib for the treatment of patients with advanced RET fusion positive non-small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 19 Feb 2025
Durvalumab in combination with etoposide phosphate and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of durvalumab (Imfinzi) in combination with etoposide ...
Posted by Michael Wonder on 13 Feb 2025
Olaparib for the treatment of patients with advanced, BRCA mutation positive, HER2 negative breast cancer after chemotherapy
12 February 2025 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the treatment of ...
Posted by Michael Wonder on 13 Feb 2025
NICE joins international collaboration on HTA methods research
12 February 2025 - We’ve partnered with the US based ICER and the Canadian Drug Agency (CDA-AMC) to establish the Health ...
Posted by Michael Wonder on 13 Feb 2025
Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration untreated with a targeted cancer medicine
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 13 Feb 2025
Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration after treatment with a targeted cancer medicine (final guidance)
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 12 Feb 2025
Ganaxolone for the treatment of patients 2 years of age and older with seizures caused by CDKL5 deficiency disorder
12 February 2025 - NICE has published final evidence-based recommendations on the use of ganaxolone (Ztalmy) for the treatment of ...
Posted by Michael Wonder on 11 Feb 2025
Nivolumab and ipilimumab for the first-line treatment of patients with metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
10 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Feb 2025
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer (final guidance)
5 February 2025 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adjuvant treatment ...
Posted by Michael Wonder on 05 Feb 2025
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, HER2 negative breast cancer with an ESR1 mutation after endocrine treatment (final guidance)
5 February 2025 - Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation ...
Posted by Michael Wonder on 04 Feb 2025
Durvalumab with tremelimumab for the first-line treatment of patients with advanced or unresectable hepatocellular carcinoma
4 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 31 Jan 2025
Thousands of people with a severe dust mite allergy are set to benefit from life-changing treatment
30 January 2025 - We've recommended an innovative daily tablet treatment shown to reduce symptoms and improve quality of life. ...
Posted by Michael Wonder on 28 Jan 2025
Spesolimab for the treatment of patients with generalised pustular psoriasis flares
24 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jan 2025
Harnessing expertise to improve patient access to innovative health technologies
28 January 2025 - Introducing the Medicines and Medical Devices Access Initiative: a new collaboration that aims to improve patient access ...